Interleukin-6 as one of the potential mediators of immune-related adverse events in non-small cell lung cancer patients treated with immune checkpoint blockade: evidence from a case report

Acta Oncol. 2018 May;57(5):705-708. doi: 10.1080/0284186X.2017.1406668. Epub 2017 Nov 24.

Authors

Abdul Rafeh Naqash¹, Li V Yang¹, Edward J Sanderlin¹, Druid C Atwell¹, Paul R Walker²

Affiliations

¹ a Division of Hematology/Oncology , East Carolina University , Greenville , NC , USA.
² b Thoracic Oncology , East Carolina University , Greenville , NC , USA.

PMID: 29171332
DOI: 10.1080/0284186X.2017.1406668

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Alveolitis, Extrinsic Allergic / chemically induced*
Alveolitis, Extrinsic Allergic / immunology
Antibodies, Monoclonal / administration & dosage
Antibodies, Monoclonal / adverse effects*
Antibodies, Monoclonal, Humanized / administration & dosage
Antibodies, Monoclonal, Humanized / adverse effects
Autoimmune Diseases / chemically induced
B7-H1 Antigen / immunology
Carcinoma, Non-Small-Cell Lung / drug therapy*
Carcinoma, Non-Small-Cell Lung / immunology
Female
Humans
Immunotherapy / adverse effects*
Immunotherapy / methods
Interleukin-6 / blood
Interleukin-6 / physiology*
Lung Neoplasms / drug therapy*
Lung Neoplasms / immunology
Middle Aged

Substances

Antibodies, Monoclonal
Antibodies, Monoclonal, Humanized
B7-H1 Antigen
CD274 protein, human
Interleukin-6
atezolizumab
tocilizumab